Entervax: Clinical Evaluation of a Bivalent Typhoid-Paratyphoid Enteric Fever Vaccine

Prokarium’s vision is a world where many different recombinant protein vaccines are delivered orally at reduced cost to improve uptake and prevent illness in populations across the globe. Entervax will be the first clinical proof-of-concept (CPoC) for achieving this using the Vaxonella platform. This CPoC is instrumental in broadening Vaxonella’s use through the future partnering with other vaccine developers wanting to apply our technologies. In a more connected world, with accelerating urbanization putting a strain on sanitation and empiric use of antibiotics leading to multi-drug resistant pathogens, chances for epidemics and pandemics are growing at an exponential rate. There is talk of a post-antibiotic era within our lifetimes and when we reach this, rapid deployment of prophylactic and therapeutic vaccines will be paramount. We envision that Vaxonella and Entervax will be able to play an important role in epidemic preparedness and response, because of the potential long shelf life, thermostable formulation and oral (self-) administration. Finally, this project will not only help Prokarium to become recognised for developing effective novel vaccines, it will also help to attract funding and talent to our growing biotech company.